Latest results from the PUP-GCP clinical trial: a low inhibitor rate in previously untreated patients with severe hemophilia A treated with octanate

被引：0
|
作者：
Klukowska, A. [1 ]
Jansen, M. [2 ]
Komrska, V. [3 ]
Laguna, P. [1 ]
Vdovin, V. [4 ]
Knaub, S. [5 ]
机构：
[1] Med Univ Warsaw, Dept Paediat Haematol & Oncol, Warsaw, Poland
[2] Octapharma Prod Gesell mbH, Vienna, Austria
[3] Univ Hosp Motol, Dept Pediat Haematol & Oncol, Prague, Czech Republic
[4] Izmaylovo Childrens Hosp, Haematol Ctr, Moscow, Russia
[5] OCTAPHARMA AG, Clin R&D Dept, Lachen, Switzerland
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：19 / 20
页数：2
相关论文
共 50 条
  • [41] The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results
    Kenet, Gili
    Chuansumrit, Ampaiwan
    Matsushita, Tadashi
    Young, Guy
    Yadav, Vandana
    Zak, Marek
    Male, Christoph
    BLOOD, 2022, 140 : 2726 - 2727
  • [42] IMMUNOGENICITY PROFILE OF RURIOCTOCOG ALFA PEGOL IN PREVIOUSLY TREATED PATIENTS WITH SEVERE CONGENITAL HEMOPHILIA A: FINDINGS FROM 6 CLINICAL TRIALS
    Horling, F. M.
    Engl, W.
    Reipert, B. M.
    Tangada, S.
    HAEMOPHILIA, 2020, 26 : 123 - 124
  • [43] Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial
    Yaish, Hassan
    Matsushita, Tadashi
    Belhani, Meriem
    Jimenez-Yuste, Victor
    Kavakli, Kaan
    Korsholm, Lars
    Matytsina, Irina
    Philipp, Claire
    Reichwald, Kirsten
    Wu, Runhui
    HAEMOPHILIA, 2020, 26 (01) : 64 - 72
  • [44] Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B
    Windyga, Jerzy
    Timofeeva, Margarita
    Stasyshyn, Oleksandra
    Mamonov, Vasily
    Lamas Castellanos, Jose Luis
    Lissitchkov, Toshko
    Chojnowski, Krzysztof
    Chapman, Miranda
    Pavlova, Borislava G.
    Tangada, Srilatha
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2020, 26
  • [45] Impact of severe hemophilia A on patients' health status: Results from the guardian™1 clinical trial of turoctocog alfa
    Ozelo, Margareth
    Chowdary, Pratima
    Regnault, Antoine
    Busk, Anne Kirstine
    HAEMOPHILIA, 2014, 20 : 171 - 172
  • [46] Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study
    Klukowska, A.
    Komrska, V.
    Jansen, M.
    Laguna, P.
    HAEMOPHILIA, 2011, 17 (03) : 399 - 406
  • [47] Safety and Efficacy of BAY 81-8973 for Surgery in Previously Treated Patients With Severe Haemophilia A: Results of The LEOPOLD Clinical Trial Program
    Oldenburg, J.
    Windyga, J.
    Hampton, K.
    Lalezari, S.
    Tseneklidou-Stoeter, D.
    Beckmann, H.
    Enriquez, M. Mass
    HAEMOPHILIA, 2015, 21 : 50 - 51
  • [48] Experiences with Efanesoctocog Alfa: Exit Interviews with Caregivers of Previously Treated Patients with Hemophilia A from the XTEND-Kids Phase 3 Clinical Trial
    Malec, Lynn
    Carcao, Manuel
    Mathias, Mary
    Kragh, Nana
    Dumont, Jennifer
    Willemze, Annemieke
    Bystricka, Linda
    Wilson, Amanda
    Dibenedetti, Dana
    BLOOD, 2023, 142
  • [49] Clinical evaluation of novel recombinant glycopegylated FVIII (turoctocog alfa pegol, N8-GP): efficacy and safety in previously treated patients with severe hemophilia A - results of pathfinder™2 international trial
    Giangrande, P.
    Chowdary, P.
    Enhrenforth, S.
    Hanabusa, H.
    Leebeek, F. W.
    Lentz, S. R.
    Nemes, L.
    Poulsen, L. H.
    Santagostino, E.
    You, C. W.
    Clausen, W. H. O.
    Oldenburg, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 176 - 176
  • [50] Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study
    Sidonio, Robert F.
    Thompson, Alexis A.
    Peyvandi, Flora
    Stasyshyn, Oleksandra
    Yeoh, Seoh Leng
    Sosothikul, Darintr
    Antmen, Ali Bulent
    Maggiore, Caterina
    Engl, Werner
    Ewenstein, Bruce
    Tangada, Srilatha
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (10) : 793 - 801
12345